Healthcare Private Placement and M&A Transactions Review Week Ending May 25, 2025

CellCentric: The company raised $120 million of Series C venture funding in a deal led by RA Capital Management and Forbion on May 19, 2025. Avego Management and BrightEdge also participated in the round. The company is an operator of a clinical-stage cancer therapy biotechnology business intended to focus on novel drug development for specific cancers.

ReAlta Life Sciences: The company raised $66.9 million of Series A venture funding from Koa Labs, and other undisclosed investors on May 20, 2025, putting the company’s pre-money valuation at $133.1 million. The company is a developer of a class of drugs with unique dual-targeting therapeutic capabilities that rebalance and complement inflammatory processes.

CoRegen: The company raised $62.6 million of Series A venture funding from undisclosed investors on May 22, 2025, putting the company’s pre-money valuation at $309.4 million. The company is a developer of a drug discovery platform intended to accelerate the development of cancer treatments.

Artedrone: The company is reportedly in the process of raising an estimated EUR 20 million of Series B venture funding on May 25, 2025. The company is a developer of autonomous robotics designed for stroke treatment and interventional neuroradiology.

SeqOne: The company raised EUR 20 million of venture funding in a deal led by Supernova Invest on May 22, 2025. Omnes Capital, Mérieux Equity Partners, Elaia Partners and other undisclosed investors also participated in the round. The company is a developer of a genomic analysis platform designed to offer analysis of genomic data.

Rhino: The company raised $15 million of Series A venture funding in a deal led by AlleyCorp on May 22, 2025, putting the company’s pre-money valuation at $45 million. TELUS Global Ventures, Bird Capital, LionBird, Fusion Fund, Qiming Venture Partners USA, Gaingels, Keren Maccabi, Frank Sica, and other undisclosed investors also participated in the round. The company is a developer of a software solution that enables organizations to perform federated learning and analytics across decentralized data sources without transferring sensitive data.

Persist AI: The company raised $12 million of Series A venture funding in a deal led by Spero Ventures on May 19, 2025. Ford Street Ventures, Purdue Ventures, Cartography Capital, Asymmetry Ventures, Innospark Ventures, Good AI Capital, MBX Capital, Global Brain, 2048 Ventures, SignalFire, Y Combinator and Eli Lilly and Company Foundation also participated in the round. The company is a developer of AI-enabled cloud formulations intended to accelerate drug development and improve patient lives.

Hemerion: The company raised EUR 6.5 million of venture funding from Fira Group, Nord France Amorçage and other undisclosed investors on May 22, 2025. The company is an operator of a biotechnology platform intended for cancer treatment.

Optura AI: The company raised $6.5 million of venture funding from Susa Ventures and undisclosed investors on May 20, 2025. The company is a developer of AI-driven enterprise software intended for improving operational efficiency and decision-making in healthcare organizations.

NTx: The company raised $4.2 million of venture funding from undisclosed investors on May 22, 2025. The company is a developer of a bioinformatics and biomanufacturing platform designed to identify, evaluate, and prioritize naturally occurring drug discovery targets.

Koning Health: The company is in the process of raising Series C venture funding from Sage Tap Poder and other undisclosed investors on May 22, 2025. The company is a developer of a computed tomography technology designed to improve the way clinicians visualize and evaluate breast tissue.

Syndicate Bio: The company received an undisclosed amount of development capital from Nubia Capital on May 20, 2025. The company is an operator of a biotechnology research business focused on genomics and precision medicine in diverse geographical regions.

EsoBiotec / AstraZeneca: The company was acquired by AstraZeneca for $1 billion on May 20, 2025. The company is a developer of immunotherapies designed to make cancer treatments more accessible, effective, and affordable.

Vigil Neuro / Sanofi: The company reached a definitive agreement to be acquired by Sanofi for approximately $470 million with a contingent value right of up to $600 million on May 21, 2025. Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in developing disease-modifying therapeutics to restore the vigilance of microglia to treat rare and common neurodegenerative diseases.

OptiNose / Paratek Pharmaceuticals: The company was acquired by Paratek Pharmaceuticals, via its financial sponsors Novo Holdings and B-FLEXION Life Sciences, through a public-to-private $330 million LBO on May 21, 2025. OptiNose Inc is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ENT and allergy specialists.

23andMe / Regeneron Pharmaceuticals: The company reached a definitive agreement to be acquired by Regeneron Pharmaceuticals for $316.5 million on May 19, 2025. 23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, through DNA collection kits shipped via mail.

Biolife Delaware / Merit Medical Systems: The company was acquired by Merit Medical Systems for $120 million on May 20, 2025. The company is a manufacturer of medical devices designed for wound care and hemostasis management.

Acelyrin / Alumis: The company was acquired by Alumis for an undisclosed amount on May 21, 2025. Acelyrin Inc is a late-stage clinical biopharmaceutical company that develops treatments for diseases with pathology related to excess activation of the immune system.

Dorian Therapeutics / Altos Labs: The company was acquired by Altos Labs, via its financial sponsors 8VC, General Catalyst and Mubadala Capital, through an LBO on May 21, 2025 for an undisclosed amount. The company is a developer of novel therapeutics designed to rejuvenate cells and tissues.

Halo Labs / Waters: The company was acquired by Waters for an undisclosed amount on May 21, 2025. The company is a scientific instrumentation and consumable company that focuses on developing and commercializing tools for particle analysis in biopharmaceutical formulations and quality control.

RedFox AI / Recovery.com: The company was acquired by Recovery.com for an undisclosed amount on May 21, 2025. The company is a developer of a digital assistant designed to improve the patient experience for at-home diagnostic testing and home healthcare.

REI AI / Kailo Medical: The company was acquired by Kailo Medical for an undisclosed amount on May 21, 2025. The company is a developer of a generative artificial intelligence platform intended for radiology reporting and clinical workflow optimization.